Dementia Treatment Market – Industry Analysis and Forecast 2027: By Drug Class, Distribution Channel, Treatment Center, End User and Region.

Dementia Treatment Market – Industry Analysis and Forecast 2027: By Drug Class, Distribution Channel, Treatment Center, End User and Region.

Market Scenario

Dementia Treatment Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a XX% CAGR of around XX% during a forecast period. Dementia Treatment Market Dementia covers a wide range of diseases and condition characterized by decline in memory, language, also comprising Alzheimer’s disease, which is most common cause of dementia. Disorders clustered below the common term “dementia” are affected by abnormal brain conditions. Dementia is a condition characterized by a deterioration in memory, language, problem-solving and other thinking skills that affect a person's capability to accomplish everyday activities. Alzheimer's is the most common cause of dementia. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The scope of the report includes a detailed study of global and regional markets for Dementia Treatment with the reasons given for variants in the growth of the industry in certain regions. Increase in R&D expenditure, raised frequency of Alzheimer’s across the globe, surged geriatric population, upsurge in awareness about neurodegenerative diseases in emerging countries, and rich pipeline of new treatment alternatives are projected to lift the dementia treatment market throughout the forecast period. Additionally, rising research and development activities in disease transforming drugs and increase in investment by key players in clinical studies of innovative treatment options are anticipated to drive the dementia treatment market during forecast period. Nevertheless, the increased cost of innovative treatments and severe adverse effects concomitant with certain treatments are anticipated to hamper the dementia treatment market. The report on dementia treatment market covers segments such as Drug Class, Distribution Channel and Region. The Drug Class segment includes Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combined Drug and Others. Among the Drug Class, Cholinergic/ Cholinesterase (ChE) Inhibitors is accounted for the largest XX% market share in the dementia treatment market. The Distribution Channel segment is further sub-segmented into Hospital Pharmacies, Retail Pharmacies, and Online Sales. Among the Distribution Channel, Hospital Pharmacies is accounted for the largest XX% market share in the Dementia Treatment Market. Based on regional segment, the global Dementia Treatment Market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America leads the dementia treatment market due to high awareness concerning Alzheimer’s disease in the U.S. and increased frequency of Alzheimer’s disease in the region. As per the World Alzheimer’s Report, Alzheimer’s is the sixth-leading reason of death in the U.S. and presently, more than X Mn Americans are reported Alzheimer’s. Increasing prevalence of Alzheimer’s in elderly age group and demand for innovative therapies and disease transforming drugs is a key factor driving the market in North America. European market demonstrated similar pattern and followed North America dementia treatment market. The market in Asia Pacific is estimated to enlarge at a considerably high CAGR throughout the forecast period, due to developing health care infrastructure and increasing awareness concerning Alzheimer’s in countries like China and India. Key players operating in the Dementia Treatment Market are Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Ltd., Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and F. Hoffmann-La Roche Ltd. The companies functioning in the market are concentrating on R&D investments and fund raining activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Dementia Treatment Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Dementia Treatment Market.

Scope of the Dementia Treatment Market

Dementia Treatment Market, By Drug Class

• Cholinergic/ Cholinesterase (ChE) Inhibitors • Memantine • Combined Drug • Others

Dementia Treatment Market, By Distribution Channel

• Hospital Pharmacies • Retail Pharmacies • Online Sales

Dementia Treatment Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Dementia Treatment Market

• Pfizer, Inc. • Merz Pharma GmbH & Co. KGaA. • Novartis AG • Allergan plc. • Daiichi Sankyo Company, Ltd. • Ono Pharmaceutical Co., Ltd. • Johnson & Johnson Services, Inc. • Eisai Co., Ltd. • H. Lundbeck A/S • F. Hoffmann-La Roche Ltd. Global Anti-aging Market 

Table of Contents

Dementia Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Dementia Treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Dementia Treatment Market Analysis and Forecast 6.1. Global Dementia Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Dementia Treatment Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Dementia Treatment Market Value Share Analysis, By Drug Class 7.4. Global Dementia Treatment Market Size (US$ Mn) Forecast, By Drug Class 7.5. Global Dementia Treatment Market Analysis, By Drug Class 7.6. Global Dementia Treatment Market Attractiveness Analysis, By Drug Class 8. Global Dementia Treatment Market Analysis and Forecast, By Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Dementia Treatment Market Value Share Analysis, By Distribution Channel 8.4. Global Dementia Treatment Market Size (US$ Mn) Forecast, By Distribution Channel 8.5. Global Dementia Treatment Market Analysis, By Distribution Channel 8.6. Global Dementia Treatment Market Attractiveness Analysis, By Distribution Channel 9. Global Dementia Treatment Market Analysis, by Region 9.1. Global Dementia Treatment Market Value Share Analysis, by Region 9.2. Global Dementia Treatment Market Size (US$ Mn) Forecast, by Region 9.3. Global Dementia Treatment Market Attractiveness Analysis, by Region 10. North America Dementia Treatment Market Analysis 10.1. Key Findings 10.2. North America Dementia Treatment Market Overview 10.3. North America Dementia Treatment Market Value Share Analysis, By Drug Class 10.4. North America Dementia Treatment Market Forecast, By Drug Class 10.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 10.4.2. Memantine 10.4.3. Combined Drug 10.4.4. Others 10.5. North America Dementia Treatment Market Value Share Analysis, By Distribution Channel 10.6. North America Dementia Treatment Market Forecast, By Distribution Channel 10.6.1. Hospital Pharmacies 10.6.2. Retail Pharmacies 10.6.3. Online Sales 10.7. North America Dementia Treatment Market Value Share Analysis, by Country 10.8. North America Dementia Treatment Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Dementia Treatment Market Analysis, by Country 10.10. U.S. Dementia Treatment Market Forecast, By Drug Class 10.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 10.10.2. Memantine 10.10.3. Combined Drug 10.10.4. Others 10.11. U.S. Dementia Treatment Market Forecast, By Distribution Channel 10.11.1. Hospital Pharmacies 10.11.2. Retail Pharmacies 10.11.3. Online Sales 10.12. Canada Dementia Treatment Market Forecast, By Drug Class 10.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 10.12.2. Memantine 10.12.3. Combined Drug 10.12.4. Others 10.13. Canada Dementia Treatment Market Forecast, By Distribution Channel 10.13.1. Hospital Pharmacies 10.13.2. Retail Pharmacies 10.13.3. Online Sales 10.14. North America Dementia Treatment Market Attractiveness Analysis 10.14.1. By Drug Class 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Dementia Treatment Market Analysis 11.1. Key Findings 11.2. Europe Dementia Treatment Market Overview 11.3. Europe Dementia Treatment Market Value Share Analysis, By Drug Class 11.4. Europe Dementia Treatment Market Forecast, By Drug Class 11.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.4.2. Memantine 11.4.3. Combined Drug 11.4.4. Others 11.5. Europe Dementia Treatment Market Value Share Analysis, By Distribution Channel 11.6. Europe Dementia Treatment Market Forecast, By Distribution Channel 11.6.1. Hospital Pharmacies 11.6.2. Retail Pharmacies 11.6.3. Online Sales 11.7. Europe Dementia Treatment Market Value Share Analysis, by Country 11.8. Europe Dementia Treatment Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Dementia Treatment Market Analysis, by Country 11.10. Germany Dementia Treatment Market Forecast, By Drug Class 11.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.10.2. Memantine 11.10.3. Combined Drug 11.10.4. Others 11.11. Germany Dementia Treatment Market Forecast, By Distribution Channel 11.11.1. Hospital Pharmacies 11.11.2. Retail Pharmacies 11.11.3. Online Sales 11.12. U.K. Dementia Treatment Market Forecast, By Drug Class 11.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.12.2. Memantine 11.12.3. Combined Drug 11.12.4. Others 11.13. U.K. Dementia Treatment Market Forecast, By Distribution Channel 11.13.1. Hospital Pharmacies 11.13.2. Retail Pharmacies 11.13.3. Online Sales 11.14. France Dementia Treatment Market Forecast, By Drug Class 11.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.14.2. Memantine 11.14.3. Combined Drug 11.14.4. Others 11.15. France Dementia Treatment Market Forecast, By Distribution Channel 11.15.1. Hospital Pharmacies 11.15.2. Retail Pharmacies 11.15.3. Online Sales 11.16. Italy Dementia Treatment Market Forecast, By Drug Class 11.16.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.16.2. Memantine 11.16.3. Combined Drug 11.16.4. Others 11.17. Italy Dementia Treatment Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Sales 11.18. Spain Dementia Treatment Market Forecast, By Drug Class 11.18.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.18.2. Memantine 11.18.3. Combined Drug 11.18.4. Others 11.19. Spain Dementia Treatment Market Forecast, By Distribution Channel 11.19.1. Hospital Pharmacies 11.19.2. Retail Pharmacies 11.19.3. Online Sales 11.20. Rest of Europe Dementia Treatment Market Forecast, By Drug Class 11.20.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 11.20.2. Memantine 11.20.3. Combined Drug 11.20.4. Others 11.21. Rest of Europe Dementia Treatment Market Forecast, By Distribution Channel 11.21.1. Hospital Pharmacies 11.21.2. Retail Pharmacies 11.21.3. Online Sales 11.22. Europe Dementia Treatment Market Attractiveness Analysis 11.22.1. By Drug Class 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Dementia Treatment Market Analysis 12.1. Key Findings 12.2. Asia Pacific Dementia Treatment Market Overview 12.3. Asia Pacific Dementia Treatment Market Value Share Analysis, By Drug Class 12.4. Asia Pacific Dementia Treatment Market Forecast, By Drug Class 12.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.4.2. Memantine 12.4.3. Combined Drug 12.4.4. Others 12.5. Asia Pacific Dementia Treatment Market Value Share Analysis, By Distribution Channel 12.6. Asia Pacific Dementia Treatment Market Forecast, By Distribution Channel 12.6.1. Hospital Pharmacies 12.6.2. Retail Pharmacies 12.6.3. Online Sales 12.7. Asia Pacific Dementia Treatment Market Value Share Analysis, by Country 12.8. Asia Pacific Dementia Treatment Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Dementia Treatment Market Analysis, by Country 12.10. China Dementia Treatment Market Forecast, By Drug Class 12.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.10.2. Memantine 12.10.3. Combined Drug 12.10.4. Others 12.11. China Dementia Treatment Market Forecast, By Distribution Channel 12.11.1. Hospital Pharmacies 12.11.2. Retail Pharmacies 12.11.3. Online Sales 12.12. India Dementia Treatment Market Forecast, By Drug Class 12.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.12.2. Memantine 12.12.3. Combined Drug 12.12.4. Others 12.13. India Dementia Treatment Market Forecast, By Distribution Channel 12.13.1. Hospital Pharmacies 12.13.2. Retail Pharmacies 12.13.3. Online Sales 12.14. Japan Dementia Treatment Market Forecast, By Drug Class 12.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.14.2. Memantine 12.14.3. Combined Drug 12.14.4. Others 12.15. Japan Dementia Treatment Market Forecast, By Distribution Channel 12.15.1. Hospital Pharmacies 12.15.2. Retail Pharmacies 12.15.3. Online Sales 12.16. ASEAN Dementia Treatment Market Forecast, By Drug Class 12.16.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.16.2. Memantine 12.16.3. Combined Drug 12.16.4. Others 12.17. ASEAN Dementia Treatment Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Sales 12.18. Rest of Asia Pacific Dementia Treatment Market Forecast, By Drug Class 12.18.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 12.18.2. Memantine 12.18.3. Combined Drug 12.18.4. Others 12.19. Rest of Asia Pacific Dementia Treatment Market Forecast, By Distribution Channel 12.19.1. Hospital Pharmacies 12.19.2. Retail Pharmacies 12.19.3. Online Sales 12.20. Asia Pacific Dementia Treatment Market Attractiveness Analysis 12.20.1. By Drug Class 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Dementia Treatment Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Dementia Treatment Market Overview 13.3. Middle East & Africa Dementia Treatment Market Value Share Analysis, By Drug Class 13.4. Middle East & Africa Dementia Treatment Market Forecast, By Drug Class 13.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 13.4.2. Memantine 13.4.3. Combined Drug 13.4.4. Others 13.5. Middle East & Africa Dementia Treatment Market Value Share Analysis, By Distribution Channel 13.6. Middle East & Africa Dementia Treatment Market Forecast, By Distribution Channel 13.6.1. Hospital Pharmacies 13.6.2. Retail Pharmacies 13.6.3. Online Sales 13.7. Middle East & Africa Dementia Treatment Market Value Share Analysis, by Country 13.8. Middle East & Africa Dementia Treatment Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Dementia Treatment Market Analysis, by Country 13.10. GCC Dementia Treatment Market Forecast, By Drug Class 13.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 13.10.2. Memantine 13.10.3. Combined Drug 13.10.4. Others 13.11. GCC Dementia Treatment Market Forecast, By Distribution Channel 13.11.1. Hospital Pharmacies 13.11.2. Retail Pharmacies 13.11.3. Online Sales 13.12. South Africa Dementia Treatment Market Forecast, By Drug Class 13.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 13.12.2. Memantine 13.12.3. Combined Drug 13.12.4. Others 13.13. South Africa Dementia Treatment Market Forecast, By Distribution Channel 13.13.1. Hospital Pharmacies 13.13.2. Retail Pharmacies 13.13.3. Online Sales 13.14. Rest of Middle East & Africa Dementia Treatment Market Forecast, By Drug Class 13.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 13.14.2. Memantine 13.14.3. Combined Drug 13.14.4. Others 13.15. Rest of Middle East & Africa Dementia Treatment Market Forecast, By Distribution Channel 13.15.1. Hospital Pharmacies 13.15.2. Retail Pharmacies 13.15.3. Online Sales 13.16. Middle East & Africa Dementia Treatment Market Attractiveness Analysis 13.16.1. By Drug Class 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Dementia Treatment Market Analysis 14.1. Key Findings 14.2. South America Dementia Treatment Market Overview 14.3. South America Dementia Treatment Market Value Share Analysis, By Drug Class 14.4. South America Dementia Treatment Market Forecast, By Drug Class 14.4.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 14.4.2. Memantine 14.4.3. Combined Drug 14.4.4. Others 14.5. South America Dementia Treatment Market Value Share Analysis, By Distribution Channel 14.6. South America Dementia Treatment Market Forecast, By Distribution Channel 14.6.1. Hospital Pharmacies 14.6.2. Retail Pharmacies 14.6.3. Online Sales 14.7. South America Dementia Treatment Market Value Share Analysis, by Country 14.8. South America Dementia Treatment Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Dementia Treatment Market Analysis, by Country 14.10. Brazil Dementia Treatment Market Forecast, By Drug Class 14.10.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 14.10.2. Memantine 14.10.3. Combined Drug 14.10.4. Others 14.11. Brazil Dementia Treatment Market Forecast, By Distribution Channel 14.11.1. Hospital Pharmacies 14.11.2. Retail Pharmacies 14.11.3. Online Sales 14.12. Mexico Dementia Treatment Market Forecast, By Drug Class 14.12.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 14.12.2. Memantine 14.12.3. Combined Drug 14.12.4. Others 14.13. Mexico Dementia Treatment Market Forecast, By Distribution Channel 14.13.1. Hospital Pharmacies 14.13.2. Retail Pharmacies 14.13.3. Online Sales 14.14. Rest of South America Dementia Treatment Market Forecast, By Drug Class 14.14.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 14.14.2. Memantine 14.14.3. Combined Drug 14.14.4. Others 14.15. Rest of South America Dementia Treatment Market Forecast, By Distribution Channel 14.15.1. Hospital Pharmacies 14.15.2. Retail Pharmacies 14.15.3. Online Sales 14.16. South America Dementia Treatment Market Attractiveness Analysis 14.16.1. By Drug Class 14.16.2. By Distribution Channel 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Distribution Channels and R&D investment 15.2.2. New Treatment Center Launches and Treatment Center Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Distribution Channels 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Pfizer, Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Treatment Center Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Merz Pharma GmbH & Co. KGaA. 15.3.3. Novartis AG 15.3.4. Allergan plc. 15.3.5. Daiichi Sankyo Company, Ltd. 15.3.6. Ono Pharmaceutical Co., Ltd. 15.3.7. Johnson & Johnson Services, Inc. 15.3.8. Eisai Co., Ltd. 15.3.9. H. Lundbeck A/S 15.3.10. F. Hoffmann-La Roche Ltd. 16. Primary Key Insights

About This Report

Report ID36603
Category Healthcare
Published DateNov 2019
No of Pages182
Contact Us
Call Now